Methylphenidate
23 NDCs across 5 manufacturers|16 Generic,7 Brand
Methylphenidate is used to treat attention deficit disorder with hyperactivity, depressive disorder and narcolepsy, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 6, 2006, and the first generic was approved Jun 19, 2020. FDA's Orange Book lists 14 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $691K on Methylphenidate across 2,039 claims for 465 beneficiaries.
Methylphenidate is available as 23 NDCs from 5 manufacturers (16 generic, 7 brand), with NADAC prices from $1.70 to $18.05 per EA — the most expensive product costs about 11× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Active FDA drug shortage
38 Methylphenidate presentations are currently listed in FDA's drug shortage database (first posted Jul 26, 2023). Shortages can move NADAC prices in the following weeks.
Total NDCs
23
16G / 7B
Manufacturers
5
competing in market
Price Spread
$1.70 – $18.05
per EA
7d Activity
avg -5.0% WoW · of 23 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Sandoz Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Central Nervous System Stimulant class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing METHYLPHENIDATE(2 pricing outliers)
Frequently Asked Questions
What is Methylphenidate used to treat?
Methylphenidate is used to treat attention deficit disorder with hyperactivity, depressive disorder and narcolepsy, per the National Library of Medicine's MED-RT classification.
When did Methylphenidate become available as a generic?
FDA approved the first generic Methylphenidate (ANDA) on Jun 19, 2020. The Orange Book currently lists 14 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Methylphenidate?
In 2024, Medicare Part D spent $691K on Methylphenidate across 2,039 claims for 465 beneficiaries.
Is Methylphenidate in shortage?
Yes — FDA's drug shortage database currently lists 38 Methylphenidate presentations with status "Current", first posted Jul 26, 2023.
How many Methylphenidate products are on the market?
The Methylphenidate drug market contains 23 NDCs from 5 manufacturers — 16 generic and 7 brand products.
What is the price range for Methylphenidate?
NADAC reference prices for Methylphenidate range from $1.6954 to $18.0490 per EA — the most expensive product costs about 11× the cheapest.
Is generic Methylphenidate cheaper than brand?
The average generic NADAC for Methylphenidate is $4.3764 per EA, versus $10.9934 for brand-labeled products — brand versions average about 2.5× the generic price.
Which manufacturers make Methylphenidate?
5 manufacturers list Methylphenidate in NADAC. Ranked by number of NDCs, the largest are Sandoz Inc. (8), Mylan Pharmaceuticals Inc. (4), Padagis US LLC (4), Noven Therapeutics, LLC (4), Neos Therapeutics Brands, LLC (3).
How has the price of Methylphenidate changed recently?
Over the past 7 days, 2 Methylphenidate NDCs rose and 17 fell, with a market-wide average change of -5.0%.